Almost two decades since the discovery of activating mutations in the tyrosine kinase domain (TKD) of the epidermal growth factor receptor (EGFR) that drive non-small cell lung cancer (NSCLC)1, tyrosine kinase inhibitors (TKIs) are now used routinely as the first-line treatment to target EGFR with significant clinical benefit. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.